Dosage guide · 10 mg vial

Tesamorelin Dosage Protocol

GHRH analogue · TH9507

The reference protocol shows 2 mg once daily for weeks 1–26. With 3 mL of bacteriostatic water, Peak's 10 mg vial is 3.33 mg/mL, so 2 mg measures 60 units (0.60 mL) on a U-100 syringe.

How oftenOnce daily

Starting dose2 mg

Start = units60 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Tesamorelin 10 mg vial

View on Peak Peptides

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About Tesamorelin References

01 · DOSAGE CHART

Tesamorelin dosage chart

Daily reference schedule · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL matches Peak's page and the PeptideDosages reference protocol, giving 3.33 mg/mL and 30 units per 1 mg.

Tesamorelin dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units	Syringe fill
Weeks 1–26Maintenance	2 mg	60 units0.6 mL

Once daily · subcutaneous injection

The reference protocol uses 2 mg once daily for 26 weeks and does not show a step-up.

Do not transfer the dose, diluent or storage directions from EGRIFTA SV or EGRIFTA WR to Peak's separate 10 mg vial.

Reference-site amounts reproduce a published 2 mg daily research schedule; Peak's separate 10 mg vial is not a TGA-registered medicine. Education only, not medical advice. Dose amounts adapted from Tesamorelin 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

12Tesamorelin 10 mg vials112 mg needed in total

681 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

4BAC water 10 mL bottles36 mL used for mixing

136Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Tesamorelin 10 mg vialPeak Peptides Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.600 mL

Equivalent U-100 volume scale position

60markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Tesamorelin

Protocol overview

Starting dose: 2 mg once daily
How it increases: No increase in the reference protocol
Frequency: Once daily
When to take it: No preferred time is established in the source
Schedule length: 26 weeks in the reference schedule
Common mix: 3 mL bacteriostatic water → 3.33 mg/mL

Storage

Before mixing: Refrigerate at 2–8 °C and protect from light.
After mixing: Keep upright at 2–8 °C, protected from light; Peak says to use within about 28 days.
Never: Freeze a mixed vial, or use it if the solution is cloudy, coloured or has particles.

How it works

Tesamorelin is a synthetic growth hormone-releasing hormone analogue. It acts through the growth hormone-releasing hormone pathway to stimulate growth hormone release and increase IGF-1.

The human evidence cited here concerns adults with HIV-associated lipodystrophy and specific studied or FDA medicine formulations. It does not establish the same effects, preparation or schedule for Peak's separate 10 mg research vial.

Illustrated mechanism explainer

What the research shows

In a 26-week randomised study of 412 adults with HIV and abdominal-fat accumulation, 2 mg subcutaneous tesamorelin daily reduced visceral adipose tissue by 15.2%, while it increased by 5.0% with placebo.
A pooled analysis of two studies randomised 806 antiretroviral-treated adults to 2 mg daily or placebo for 26 weeks; the reported visceral-fat treatment effect was −15.4%, with reductions maintained to week 52 in participants who continued tesamorelin.
US FDA labels restrict EGRIFTA to reduction of excess abdominal fat in HIV-infected adults with lipodystrophy and state it is not indicated for weight-loss management. The current EGRIFTA SV dose is 1.4 mg daily and EGRIFTA WR dose is 1.28 mg daily; the formulations are not substitutable.
The official ARTG search returned no result for EGRIFTA. Peak supplies its 10 mg tesamorelin listing for in-vitro research only, not as a TGA-registered medicine.

Reported side effects

In the 412-participant, 26-week study, adverse events did not differ significantly between groups, but more tesamorelin participants withdrew because of an adverse event.
The current EGRIFTA labels list arthralgia, injection-site redness or itching, limb pain, peripheral oedema and myalgia among the most common reactions, each reported in more than 5% of patients.
The EGRIFTA labels warn of elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and injection-site reactions. These warnings concern the specific FDA medicine formulations.

Important notes

Peak's 10 mg vial is supplied for in-vitro research only and is not a TGA-registered medicine.
EGRIFTA SV and EGRIFTA WR are specific FDA-approved US medicine formulations for HIV-associated lipodystrophy; their current labelled doses, diluents, preparation and storage rules do not apply to Peak's vial.
Prohibited in sport: the 2026 WADA List names tesamorelin under S2.2.4 growth hormone-releasing hormone analogues, prohibited at all times.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Tesamorelin questions

How many units is 2 mg of Tesamorelin from a 10 mg vial?

With 3 mL in a 10 mg vial, the concentration is 3.33 mg/mL. A 2 mg amount is 60 units, or 0.60 mL, on a U-100 syringe.

How much bacteriostatic water for Tesamorelin 10 mg?

The default mix is 3 mL, matching the reference protocol and Peak's page. It gives 3.33 mg/mL, where 1 mg is 30 units and 2 mg is 60 units on a U-100 syringe.

How long does a 10 mg Tesamorelin vial last?

At the 2 mg once-daily reference amount, a nominal 10 mg vial contains five daily amounts. This is a vial-yield calculation, not a beyond-use period.

Is Peak's 10 mg vial the same as EGRIFTA?

No. EGRIFTA SV is a 2 mg single-dose FDA medicine with a 1.4 mg daily label dose, and EGRIFTA WR is an 11.6 mg multidose FDA medicine with a 1.28 mg daily label dose. Their instructions do not transfer to Peak's separate 10 mg research vial.

07 · SOURCES